Leerink Cuts BioMarin Pharmaceutical Inc. (BMRN) Price Target to $60, Citing Valuation and Competitive Challenges

Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best biotech stocks to buy according to Wall Street analysts. On November 18, BioMarin Pharmaceutical (NASDAQ:BMRN) presented at the Jefferies London Healthcare Conference, where CEO Alexander outlined progress on the company’s $500 million cost transformation program, now about two-thirds complete, and announced a goal of reaching a 40% non-GAAP operating margin next year, up from 19% in 2023. Leerink Cuts BioMarin Pharmaceutical Inc. (BMRN) Price ...